Refine your search with filters

All-Materials All
Congress-AbstractsCongress Abstracts
Tools-SkillsTools & Skills
PublicationsPublications
Congress-SlidesCongress Presentations
Videos-PodcastsVideos & Podcasts

Quicksearch

DOP074: Pharmacokinetics and exposure-response of tofacitinib in a Phase 3 maintenance study in ulcerative colitis patientsECCO '17 Barcelona
Year: 2017
Authors:

Mukherjee A.*1, D'Haens G.R.2, Sandborn W.J.3, Tsuchiwata S.4, Vong C.5, Deng C.6, Xie R.6, Hazra A.1, Martin S.W.5, Friedman G.7, Niezychowski W.7, Su C.7

1Pfizer Inc, Groton, CT, United States 2Department of Gastroenterology, Academic Medical Centre, Amsterdam, Netherlands 3Division of Gastroenterology, University of California, San Diego, La Jolla, CA, United States 4Pfizer Japan Inc, Tokyo, Japan 5Pfizer Inc, Cambridge, MA, United States 6Pfizer Inc, Shanghai, China 7Pfizer Inc, Collegeville, PA, United States

DOP075: Efficacy of filgotinib, a selective JAK1 inhibitor, is independent of prior anti-TNF exposure: subgroup analysis of the phase 2 FITZROY study in moderate-to-severe Crohn's diseaseECCO '17 Barcelona
Year: 2017
Authors:

D'Haens G.1, Schreiber S.2, Petryka R.3, Kuehbacher T.4, Hebuterne X.5, Roblin X.6, Klopocka M.7, Goldis A.8, Wisniewska-Jarosinska M.9, Baranovsky A.10, Sike R.11, Stoyanova K.12, Meuleners L.13, Tasset C.13, Van der Aa A.13, Harrison P.13, Vermeire S.*14

1Academic Medical Center (AMC), Department of Gastroenterology, Amsterdam, Netherlands 2University Medical Center Schleswig-Holstein Kiel, Department of Internal Medicine I, Kiel, Germany 3Vivamed, Warsaw, Poland 4Asklepios Hospital West Hamburg, Department of Gastroenterology, Hamburg, Germany 5CHU Nice Hopital l'Archet, Department of Gastroenterology and Nutrition, Nice Cedex 3, France 6North Hospital, Department of Gastroenterology, Saint Priez en Jarez, France 7NC University in Toruń, Collegium Medicum, Bydgoszcz, Poland 8Dr. Goldis Center for Gastroenterology, Ltd., Timisoara, Romania 9Santa LLC, Santa Familia Research, Prevention and Treatment Centre, Lodz, Poland 10City Clinical Hospital #31, St. Petersburg, Russian Federation 11Szent Margit Hospital, Budapest, Hungary 12PSI Pharma Support EOOD, Sofia, Bulgaria 13Galapagos NV, Mechelen, Belgium 14University Hospitals Leuven, Department of Gastroenterology, Leuven, Belgium

DOP076: A phase 2B, multicenter, randomized, placebo-controlled dose-ranging trial of peficitinab, an oral JAK inhibitor, in patients with moderately to severely active ulcerative colitisECCO '17 Barcelona
Year: 2017
Authors:

Sands B.*1, Sandborn W.2, Feagan B.G.3, Lichtenstein G.4, Zhang H.5, Szapary P.5, Panes J.6, Vermeire S.7, O'Brien C.5, Dewey J.5, Yang Z.5, Johanns J.5, Strauss R.5, Marano C.5

1Icahn School of Medicine at Mt Sinai, New York, United States 2University of California San Diego, La Jolla, United States 3Robarts Clinical Trials, Robarts Research Institute, Western University, London, Canada 4University of Pennsylvania, Philadelphia, United States 5Janssen Research & Development, LLC, Spring House, United States 6Hospital Clinic Barcelona, IDIBAPS, CIVERehd, Barcelona, Spain 7Uz Leuven, Campus Gasthuisberg, Leuven, Belgium

DOP077: Immunomodulatory effects of etrasimod (APD334), an oral, potent, next-generation, selective S1P receptor modulatorECCO '17 Barcelona
Year: 2017
Authors:

Lee S.D.*1, Christopher R.2, Trokan L.2, Lassen C.2, Adams J.2, Chiorean M.3

1University of Washington Medical Center, Seattle, United States 2Arena Pharmaceuticals, Inc., San Diego, United States 3Virginia Mason, Digestive Disease Institute, Seattle, United States

DOP078: Pharmacology and safety of etrasimod (APD334), an oral, potent, next-generation, selective S1P receptor modulatorECCO '17 Barcelona
Year: 2017
Authors:

Kühbacher T.*1, Christopher R.2, Trokan L.2, Lassen C.2, Adams J.2, Peyrin-Biroulet L.3

1Asklepios Westklinikum Hamburg and Christian Albrechts University, Department of Internal Medicine/Gastroenterology, Kiel, Germany 2Arena Pharmaceuticals, Inc., San Diego, United States 3Nancy University Hospital and Lorraine University, Department of Gastroenterology, Nancy, France

DOP079: The role of intestinal transplant in patients with complicated inflammatory bowel disease: the Cambridge experienceECCO '17 Barcelona
Year: 2017
Authors:

Yeap S.P.*1, Sharkey L.M.1, Woodward J.M.1, Massey D.C.1, Middleton S.J.1, Russell N.K.2, Butler A.J.2

1Addenbrooke's Hospital, Gastroenterology, Cambridge, United Kingdom 2Addenbrooke's Hospital, Transplant Surgery, Cambridge, United Kingdom

DOP080: Low viral richness at baseline in ulcerative ulcerative colitis associated with faecal microbiota transplantation successECCO '17 Barcelona
Year: 2017
Authors:

Conceição-Neto N.*1, Deboutte W.1, Dierckx T.1, Machiels K.2, Wang J.1,3, Yinda C.1, Maes P.1, Van Ranst M.1, Joossens M.1,3, Raes J.1,3, Vermeire S.2, Matthijnssens J.1

1KU Leuven, Rega Institute, Department of Microbiology and Immunology, Leuven, Belgium 2KU Leuven, TARGID, Department of Translational Research Centre for GastroIntestinal Disorders (TARGID), Leuven, Belgium 3VIB, Center for the Biology of Disease, Leuven, Belgium

DOP081: Glycosylation of T cells: a novel targeted-specific therapeutic strategy in IBDECCO '17 Barcelona
Year: 2017
Authors:

Dias A.M.*1,2, Correia A.3, Pereira M.1, Almeida C.R.4, Alves I.1, Lima M.5,6, Marcos-Pinto R.2,7,8, Reis C.A.1,2,9, Vilanova M.2,3, Lago P.8, Pinho S.S.1,9

1Institute of Molecular Pathology and Immunology of the University of Porto (IPATIMUP) & i3S – Instituto de Investigação e Inovação em Saúde, Glycobiology in Cancer, Porto, Portugal 2Institute of Biomedical Sciences of Abel Salazar (ICBAS), University of Porto, Porto, Portugal 3Instituto de Investigação e Inovação em Saude (I3S)/Institute for Molecular and Cell Biology (IBMC), Immunobiology Group, Porto, Portugal 4Instituto de Investigação e Inovação em Saude (I3S)/ Institute of Biomedical Engineering (INEB), NEWTherapies Group, University of Porto, Porto, Portugal 5Centro Hospitalar do Porto, Multidisciplinary Unit for Biomedical Research (UMIB), Porto, Portugal 6Centro Hospitalar do Porto, Hematology Department, Porto, Portugal 7Medical Faculty, Centre for Research in HealthTechnologies and Information Systems (CINTESIS), Porto, Portugal 8Centro Hospitalar do Porto, Department of Gastroenterology, Porto, Portugal 9University of Porto, Medical Faculty, Porto, Portugal

DOP082: Enhanced TH17 responses in patients with IL10 receptor deficiency and history of infantile-onset IBDECCO '17 Barcelona
Year: 2017
Authors:

Shouval D.*1, Konnikova L.2, Werner L.1, Nunberg M.1, Weiss B.1, Glover S.3, Snapper S.2

1Safra Children's Hospital, Pediatric Gastroenterology, Tel Hashomer, Israel 2Boston Children's Hospital, Boston, United States 3University of Florida, Gainesville, United States

DOP083: Recombinant subcutaneous human beta-Defensin 2 (hBD2) ameliorates experimental colitis in different in vivo modelsECCO '17 Barcelona
Year: 2017
Authors:

Mailänder-Sánchez D.1, Kjaerulf S.2, Sidelmann Brinch K.2, Andersen B.2, Stange E.F.1, Malek N.1, Nordkild P.3, Wehkamp J.*1

1University Hospital Tuebingen, Internal Medicine I, Tuebingen, Germany 2Novozymes, Bagsvaerd, Denmark 3Defensin Therapeutics, Copenhagen N, Denmark

DOP084: Peripheral T cell repertoire reconstitution in Crohn's disease patients undergoing autologous HSCTECCO '17 Barcelona
Year: 2017
Authors:

Corraliza A.M.*1, Masamunt M.C.1, Ricart E.1, Lόpez-García A.1, Le Bourhis L.2, Allez M.2, Panés J.1, Salas A.1

1IDIBAPS, Hospital Clínic, Gastroenterology, Barcelona, Spain 2Hôpital Saint-Louis, Inserm U1160, Paris, France

DOP085: Tight NADPH oxidase regulation is a prerequisite for gut healthECCO '17 Barcelona
Year: 2017
Authors:

Aviello G.*1,2, Conroy E.3, Bourke B.1, Knaus U.G.1,3

1National Children's Research Centre, Our Lady's Children's Hospital, Dublin, Ireland 2University of Aberdeen, The Rowett Institute, Aberdeen, United Kingdom 3University College Dublin, Conway Institute, Dublin, Ireland

DOP086: Macrophages from Crohn's disease patients showed a defect to control adherent-invasive Escherichia coli replication influenced by genetic host factorsECCO '17 Barcelona
Year: 2017
Authors:

Buisson A.*1,2, Vazeille E.1,2, Ouchchane L.3, Goutte M.1,2, Hugot J.-P.4, Dubois A.2, Minet Quinard R.5, Bouvier D.5, Bommelaer G.1,2, Barnich N.2

1University Hospital Estaing, Gastroenterology Department, Clermont-Ferrand, France 2UMR 1071 Inserm/Université d'Auvergne; USC-INRA 2018, Microbes, Intestine, Inflammation and Susceptibility of the host, Clermont-Ferrand, France 3University Hospital G Montpied, Biostatistics unit, clermont-Ferrand, France 4Assistance Publique Hôpitaux de Paris et Université, Paris Diderot, Paris, UMR843, Inserm, Paris, France 5University Hospital G. Montpied, Biochemistry laboratory, Clermont-Ferrand, France

DOP087: Microbial colonization at weaning period determines colitis severity in adult miceECCO '17 Barcelona
Year: 2017
Authors:

Al Nabhani Z., Dulauroy S., Polomack B., Eberl G.

Institut Pasteur, Immunology Department, Paris, France

DOP088: Somatic and visceral hypersensitivity associated to acute intestinal inflammation are absent in sigma 1 receptor knockout miceECCO '17 Barcelona
Year: 2017
Authors:

Lόpez-Estévez S.*1, Gris G.2, de la Puente B.2, Codony X.2, Merlos M.2, Martínez V.1

1Universitat Autònoma de Barcelona, Cell Biology, Physiology and Immumology, Bellaterra, Spain 2Esteve, Department of Pharmacology, Drug Discovery & Preclinical Development, Barcelona, Spain

DOP089: PTPN2 controls intestinal inflammation and promotes colitis-associated tumour formation via control of inflammasome activation and IL-1alpha releaseECCO '17 Barcelona
Year: 2017
Authors:

Spalinger M.*1, Hering L.1, Manzini R.1, Riggs J.B.1, Gottier C.1, Atrott K.1, Fettelschoss A.2, Kündig T.2, Fried M.1,3, Rogler G.1,3, Scharl M.1,3

1University Hospital Zurich, Division of Gastroenterology and Hepatology, Zürich, Switzerland 2University Hospital Zürich, Clinic for Dermatology, Zürich, Switzerland 3University of Zurich, Zurich Center for Integrative Human Physiology, Zürich, Switzerland

DOP090: The α7 nicotinic acetylcholine receptor agonist GTS-21 attenuate DSS-induced colitis by improving intestinal mucosal barrier functionECCO '17 Barcelona
Year: 2017
Authors:

Zhang H.*1, Zhu Y.2

1the First Affiliated Hospital of Nanjing Medical University, Gastroenterology, Nanjing, China 2the First Affiliated Hospital of Nanjing Medical University, Nanjing, China

N795: Fatigue in IBD must be to compared to the background population – generation of normative data for the IBD-FECCO '17 Barcelona
Year: 2017
Authors:

Bager P.*1, Vestergaard C.1, Juul T.2, Dahlerup J.F.1

1Aarhus University Hospital, Department of Hepatology and Gastroenterology, Aarhus, Denmark 2Aarhus University Hospital, Department of Surgery, Aarhus, Denmark

N796: Emotional en social functioning in patients with Crohn's disease needs more attentionECCO '17 Barcelona
Year: 2017
Authors:

Wisse J.*1, Smids C.1, Heida W.1, Calsbeek H.2, Horjus Talabur Horje C.1, de Leest M.1, Groenen M.1, Wahab P.1

1Rijnstate Hospital, IBD centre, Gastroenterology and Hepatology, Arnhem, Netherlands 2IQ Healthcare, Radboud Institute for Health Sciences, Nijmegen, Netherlands

N797: Therapeutic drug monitoring after thiopurine initiation improves drug efficacyECCO '17 Barcelona
Year: 2017
Authors:

Dijkstra-Heida W.*1, Smids C.1, van Luin M.2, Huisman-de Waal G.3, de Leest M.1, Horjus Talabur Horje C.1, Wisse J.1, Wahab P.1, Groenen M.1

1Rijnstate Hospital, IBD centre, Gastroenterology and Hepatology, Arnhem, Netherlands 2Rijnstate Hospital, Pharmacy, Arnhem, Netherlands 3IQ healthcare, Radboud Insitute for Health Sciences, Nijmegen, Netherlands